This is a prospective, open-label, single-center clinical trial. This study will evaluate the
safety and efficacy of BCMA CAR-NK cells in the treatment of relapsed or/and refractory MM.
The primary endpoints are dose limiting toxicity (DLT) and Maximal tolerability evaluation
(MTD).